AU2007318922C1 - Pyrimidine derivatives as POSH and POSH-AP inhibitors - Google Patents

Pyrimidine derivatives as POSH and POSH-AP inhibitors Download PDF

Info

Publication number
AU2007318922C1
AU2007318922C1 AU2007318922A AU2007318922A AU2007318922C1 AU 2007318922 C1 AU2007318922 C1 AU 2007318922C1 AU 2007318922 A AU2007318922 A AU 2007318922A AU 2007318922 A AU2007318922 A AU 2007318922A AU 2007318922 C1 AU2007318922 C1 AU 2007318922C1
Authority
AU
Australia
Prior art keywords
compound
posh
alkyl
aryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007318922A
Other languages
English (en)
Other versions
AU2007318922A1 (en
AU2007318922B2 (en
Inventor
Itzchak Angel
Maxim Borovitov
Nurit Livnah
Philippe Nakache
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteologics Ltd
Original Assignee
Proteologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteologics Ltd filed Critical Proteologics Ltd
Publication of AU2007318922A1 publication Critical patent/AU2007318922A1/en
Application granted granted Critical
Publication of AU2007318922B2 publication Critical patent/AU2007318922B2/en
Publication of AU2007318922C1 publication Critical patent/AU2007318922C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2007318922A 2006-11-07 2007-11-07 Pyrimidine derivatives as POSH and POSH-AP inhibitors Ceased AU2007318922C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85737806P 2006-11-07 2006-11-07
US60/857,378 2006-11-07
US95983107P 2007-07-17 2007-07-17
US60/959,831 2007-07-17
PCT/IL2007/001356 WO2008056356A2 (en) 2006-11-07 2007-11-07 Pyrimidine derivatives as posh and posh-ap inhibitors

Publications (3)

Publication Number Publication Date
AU2007318922A1 AU2007318922A1 (en) 2008-05-15
AU2007318922B2 AU2007318922B2 (en) 2013-01-10
AU2007318922C1 true AU2007318922C1 (en) 2013-09-12

Family

ID=39364907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007318922A Ceased AU2007318922C1 (en) 2006-11-07 2007-11-07 Pyrimidine derivatives as POSH and POSH-AP inhibitors

Country Status (6)

Country Link
US (2) US8283355B2 (https=)
EP (1) EP2083826A4 (https=)
JP (1) JP2010509205A (https=)
AU (1) AU2007318922C1 (https=)
CA (1) CA2668859A1 (https=)
WO (1) WO2008056356A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512234A (ja) * 2009-11-30 2013-04-11 プロテオロジクス リミテッド 小型ピリミジン誘導体およびその使用の方法
WO2013088445A1 (en) * 2011-12-13 2013-06-20 Proteologics Ltd Pyrimidine derivatives for treatment of inflammatory diseases
GB201415688D0 (en) * 2014-09-04 2014-10-22 Univ Edinburgh Method and Systems
JP6993318B2 (ja) * 2015-07-15 2022-02-03 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ Ｂ型肝炎ウイルス複製の調節
US12059413B2 (en) 2016-11-02 2024-08-13 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction
EP3818051B1 (en) * 2018-07-05 2022-08-03 Bayer Aktiengesellschaft Substituted thiophenecarboxamides and analogues as antibacterials agents
EP3949963A4 (en) * 2019-04-02 2023-01-04 Yonsei University, University-Industry Foundation(UIF). NEW COMPOUND AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF RESPIRATORY DISEASES COMPRISING THIS AS AN ACTIVE PRINCIPLE
CN110760597B (zh) * 2019-11-22 2022-08-23 西北农林科技大学 一种检测黄牛ncstn基因拷贝数变异的方法及其应用
WO2025117616A1 (en) * 2023-11-27 2025-06-05 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014807A1 (en) * 2004-07-19 2006-01-19 Lin Leu-Fen H Neuroprotective small organic molecules, compositions and uses related thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734081A (en) * 1994-08-05 1998-03-31 Warner-Lambert Company Arylthio compounds
AU2002221565A1 (en) * 2000-12-08 2002-06-18 Novo-Nordisk A/S Trefoil factor 2 (tff2) peptides with moiety attached to asn15
FI116940B (fi) * 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
US7262185B2 (en) * 2001-08-08 2007-08-28 Takeda Chemical Industries Ltd. Benzazepine derivative, process for producing the same, and use
FR2845382A1 (fr) * 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
US8202861B2 (en) * 2003-08-08 2012-06-19 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
US20050214751A1 (en) * 2004-03-02 2005-09-29 Proteologics, Inc. Inhibition of viral maturation, methods and compositions related thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014807A1 (en) * 2004-07-19 2006-01-19 Lin Leu-Fen H Neuroprotective small organic molecules, compositions and uses related thereto

Also Published As

Publication number Publication date
EP2083826A2 (en) 2009-08-05
US8283355B2 (en) 2012-10-09
AU2007318922A1 (en) 2008-05-15
US20130131094A1 (en) 2013-05-23
WO2008056356A3 (en) 2009-09-03
CA2668859A1 (en) 2008-05-15
WO2008056356A2 (en) 2008-05-15
EP2083826A4 (en) 2010-09-22
JP2010509205A (ja) 2010-03-25
US20100179178A1 (en) 2010-07-15
AU2007318922B2 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
AU2007318922C1 (en) Pyrimidine derivatives as POSH and POSH-AP inhibitors
US9765019B2 (en) Small-molecule-targeted protein degradation
US7659277B2 (en) Ubiquitin ligase inhibitors and methods related thereto
AU2004268647B2 (en) Modulation of beta-catenin/TCF activated transcription
US20040259880A1 (en) Pyrrole compounds and uses thereof
US20120135089A1 (en) E3 ligase inhibitors
DK2780326T3 (en) PROCEDURE FOR INHIBITING DEUBIQUITINATION ACTIVITY
WO2005060956A1 (en) IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
CN107531683B (zh) Usp7抑制剂化合物及使用方法
Blaquiere et al. Medicinal chemistry of inhibiting RING-type E3 ubiquitin ligases
CN114025766B (zh) 用于抑制gapdh的噁噻嗪化合物
US20120015967A1 (en) Pyrimidine and pyridine derivatives as posh and posh-ap inhibitors
EP1646644A2 (en) Posh interacting proteins and related methods
AU2005279845A1 (en) Inhibition of viruses using RNase H inhibitors
US20060286630A1 (en) Posh interacting proteins and related methods
Quezada Meza PROTEIN KINASE CK2 IN HUMAN DISEASES: TOO MUCH OR TOO LITTLE?
CN109790523A (zh) 组合物及其用途
Shouksmith Design and synthesis of small-molecule inhibitors targeting the SCFSKP2 E3 ligase and the MDMX-p53 interaction for cancer therapy
Sharma Strategic improvements in efficacy of DNA damaging chemotherapeutic drugs through modulation of survival factors
HK1248684B (en) Usp7 inhibitor compounds and methods of use
WO2009063412A1 (en) Use of chemical compounds for the treatment of aids

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 APR 2013 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 APR 2013

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired